Zylox-Tonbridge Reshapes Concert Party, Clarifies 24.61% Voting Bloc

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) just unveiled an announcement.

Zylox-Tonbridge Medical Technology disclosed that its existing concert party arrangement among key founders and investment entities has been revised through a supplemental agreement. Under this update, WEA Enterprises, LLC and early investor Dr. Shengping Sam Zhong have exited the concert party, and will no longer be deemed to act in concert with the remaining shareholders.

Following the change, the remaining New Concert Parties, led by founder Dr. Jonathon Zhong Zhao and several investment partnerships, will continue to coordinate their voting on company matters. Together they are deemed under Hong Kong securities law to hold a combined 84,697,302 shares, representing about 24.61% of the company’s issued share capital, which clarifies the control structure and concerted voting influence within the shareholder base.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. is a China-incorporated medical technology company listed in Hong Kong. The group focuses on developing and commercializing medical products, operating through both H shares and domestic shares with a diversified shareholder base, including founders and institutional investment partnerships.

Average Trading Volume: 725,695

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.3B

For detailed information about 2190 stock, go to TipRanks’ Stock Analysis page.